Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | SGMS1 | Q86VZ5 | 2/20 | 0.31 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21071514 | 0.89 | DDB1 (0.44) | DDB1CRBN | |
| SCHEMBL21069259 | 0.82 | DDB1 (0.44) | DDB1CRBNGPR119 | |
| SCHEMBL29347155 | 0.79 | HTR4 (0.34) | CCR5DDB1CRBN | |
| SCHEMBL24046568 | 0.79 | DDB1 (0.38) | DDB1CRBN | |
| SCHEMBL21071213 | 0.79 | DDB1 (0.45) | CCR5DDB1CRBN | |
| SCHEMBL29692737 | 0.77 | DDB1 (0.40) | DDB1CRBN | |
| SCHEMBL23808017 | 0.77 | DDB1 (0.40) | DDB1CRBN | |
| SCHEMBL23808007 | 0.77 | DDB1 (0.40) | DDB1CRBN | |
| SCHEMBL29692639 | 0.77 | DDB1 (0.40) | DDB1CRBN | |
| SCHEMBL21070936 | 0.76 | DDB1 (0.44) | CCR5DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HTR6 3032/4885NAMPT 1694/4885ALOX5AP 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.